Carolina Beltrán-Pavez
A5018245087- HIV Research and Treatment
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- SARS-CoV-2 detection and testing
- HIV/AIDS drug development and treatment
- COVID-19 and Mental Health
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Immune Cell Function and Interaction
- Biosensors and Analytical Detection
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- COVID-19 diagnosis using AI
- Mosquito-borne diseases and control
Instituto Ramón y Cajal de Investigación Sanitaria
2020-2023
Hospital Universitario Ramón y Cajal
2023
University of Chile
2020-2021
Instituto de Salud Carlos III
2021
Universitat de Barcelona
2021
Centro de Investigación Biomédica en Red
2020
Universidad de Santiago de Chile
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2018
Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP in COVID-19 progression.The study was an open-label, single-center randomized clinical trial performed academic medical center Santiago, Chile, from May 10, 2020, July 18, final follow-up until August 17, 2020. The included within first 7 days symptom onset, presenting risk factors...
Abstract The aim of this transversal study was to describe the virological and immunological features HIV-infected youths transferred from pediatric adult care units since 1997 vs. non-transferred patients Madrid Cohort children adolescents in Spain. We included 106 184 under clinical follow-up 17 public hospitals by end December 2017. Virological outcomes were compared patients. ART drug resistance mutations HIV-variants analyzed all subjects with available pol genotypes and/or genotypic...
An HIV-1–based pseudotype allows the rapid quantification of neutralizing antibody titers against SARS-CoV-2 spike protein.
Abstract The ongoing COVID-19 pandemic has reached more than 200 countries and territories worldwide. Given the large requirement of SARS-CoV-2 diagnosis considering that RNA extraction kits are in short supply, we investigated whether two commercial RT-qPCR were compatible with direct detection from nasopharyngeal swab samples. We show one tested is fully suggesting omission an step should be considered diagnosis.
Abstract Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP in COVID-19 progression. Methods Open-label, single-center, randomized clinical trial performed an academic center Santiago, Chile from May 10, 2020, July 18, final follow-up August 17, 2020. The included within first 7 days symptoms onset, presenting risk...
Longitudinal studies in HIV-1-infected individuals have indicated that 2 to 3 years of infection are required develop broadly neutralizing antibodies. However, we previously identified with activity (bNA) early HIV-1 infection, indicating a vaccine may be capable bNA induction after short periods antigen exposure. Here, describe 5 envelope sequences from who developed within the first 100 days (early neutralizers) and selected two them design immunogens based on HIV-1-Gag virus-like...
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that ability an epitope to elicit effective humoral immunity depends its exposure virion, we have used a reverse genetics approach select variants from AC10_29 randomly mutated envelope library showed increased affinity for selected bNAb (4E10 targeting MPER region). Isolated sequences were analyzed...
COVID-19 is a pandemic caused by SARS-CoV-2. In Chile, half million people have been infected and more than 16,000 died from COVID-19. As part of the clinical trial NCT04384588, we quantified IgG against S1-RBD SARS-CoV-2 (anti-RBD) in recovered Santiago evaluated their suitability as convalescent plasma donors. ELISA luminescent pseudotype were used for neutralizing antibody quantification. 72.9% population (468 639) showed seroconversion (5-55 μg/mL anti-RBD IgG) suitable candidates...
Virologic characterization of newly HIV-diagnosed adolescents could help to improve their specific needs. The objective was describe the transmitted drug resistance mutations (TDR) and its transmission by clusters in this population Spain.TDR retrotranscriptase protease inhibitors included WHO TDR list 2009 implemented Calibrated Population Resistance tool v8.0 (Stanford) were studied HIV pol sequences from all (12-19-year-old) enrolled during 2004-2019 period Spanish pediatric adult...
The Isavirus is an orthomyxovirus with a genome composed of eight segments negative single-strand RNA (-ssRNA). It has been proposed that the genomic are organized as ribonucleoprotein (RNP) complex called minigenome, which contains all viral segments, heterotrimeric polymerase and multiple copies nucleoprotein (NP). Here, we develop minigenome system show importance formation active RNPs role NP R189, R194, R302 K325 residues in RNA-binding domain context RNPs. results indicate it possible...
We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) youths with perinatal HIV, virological control and who previously carried these resistance historic plasma samples.We included vertically HIV-infected youths/young adults aged ≥10 years Madrid Cohort HIV-1 Infected Children Adolescents, exposed to lamivudine emtricitabine, samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), available PBMCs Spanish HIV...